• Je něco špatně v tomto záznamu ?

Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies

L. Ekholm, S. Vosslamber, A. Tjärnlund, TD. de Jong, Z. Betteridge, N. McHugh, L. Plestilova, M. Klein, L. Padyukov, AE. Voskuyl, IE. Bultink, D. Michiel Pegtel, CP. Mavragani, MK. Crow, J. Vencovsky, IE. Lundberg, CL. Verweij,

. 2016 ; 84 (2) : 100-9.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013861
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Medline Complete (EBSCOhost) od 1972-01-01 do Před 1 rokem
Wiley Free Content od 1997 do Před 1 rokem

Odkazy

PubMed 27173897
DOI 10.1111/sji.12449
Knihovny.cz E-zdroje

Myositis is a heterogeneous group of autoimmune diseases, with different pathogenic mechanisms contributing to the different subsets of disease. The aim of this study was to test whether the autoantibody profile in patients with myositis is associated with a type I interferon (IFN) signature, as in patients with systemic lupus erythematous (SLE). Patients with myositis were prospectively enrolled in the study and compared to healthy controls and to patients with SLE. Autoantibody status was analysed using an immunoassay system and immunoprecipitation. Type I IFN activity in whole blood was determined using direct gene expression analysis. Serum IFN-inducing activity was tested using peripheral blood cells from healthy donors. Blocking experiments were performed by neutralizing anti-IFNAR or anti-IFN-α antibodies. Patients were categorized into IFN high and IFN low based on an IFN score. Patients with autoantibodies against RNA-binding proteins had a higher IFN score compared to patients without these antibodies, and the IFN score was related to autoantibody multispecificity. Patients with dermatomyositis (DM) and inclusion body myositis (IBM) had a higher IFN score compared to the other subgroups. Serum type I IFN bioactivity was blocked by neutralizing anti-IFNAR or anti-IFN-α antibodies. To conclude, a high IFN score was not only associated with DM, as previously reported, and IBM, but also with autoantibody monospecificity against several RNA-binding proteins and with autoantibody multispecificity. These studies identify IFN-α in sera as a trigger for activation of the type I IFN pathway in peripheral blood and support IFN-α as a possible target for therapy in these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013861
003      
CZ-PrNML
005      
20170425125836.0
007      
ta
008      
170413s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/sji.12449 $2 doi
035    __
$a (PubMed)27173897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ekholm, L $u Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden.
245    10
$a Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies / $c L. Ekholm, S. Vosslamber, A. Tjärnlund, TD. de Jong, Z. Betteridge, N. McHugh, L. Plestilova, M. Klein, L. Padyukov, AE. Voskuyl, IE. Bultink, D. Michiel Pegtel, CP. Mavragani, MK. Crow, J. Vencovsky, IE. Lundberg, CL. Verweij,
520    9_
$a Myositis is a heterogeneous group of autoimmune diseases, with different pathogenic mechanisms contributing to the different subsets of disease. The aim of this study was to test whether the autoantibody profile in patients with myositis is associated with a type I interferon (IFN) signature, as in patients with systemic lupus erythematous (SLE). Patients with myositis were prospectively enrolled in the study and compared to healthy controls and to patients with SLE. Autoantibody status was analysed using an immunoassay system and immunoprecipitation. Type I IFN activity in whole blood was determined using direct gene expression analysis. Serum IFN-inducing activity was tested using peripheral blood cells from healthy donors. Blocking experiments were performed by neutralizing anti-IFNAR or anti-IFN-α antibodies. Patients were categorized into IFN high and IFN low based on an IFN score. Patients with autoantibodies against RNA-binding proteins had a higher IFN score compared to patients without these antibodies, and the IFN score was related to autoantibody multispecificity. Patients with dermatomyositis (DM) and inclusion body myositis (IBM) had a higher IFN score compared to the other subgroups. Serum type I IFN bioactivity was blocked by neutralizing anti-IFNAR or anti-IFN-α antibodies. To conclude, a high IFN score was not only associated with DM, as previously reported, and IBM, but also with autoantibody monospecificity against several RNA-binding proteins and with autoantibody multispecificity. These studies identify IFN-α in sera as a trigger for activation of the type I IFN pathway in peripheral blood and support IFN-α as a possible target for therapy in these patients.
650    _2
$a senioři $7 D000368
650    12
$a specificita protilátek $7 D000918
650    _2
$a autoprotilátky $x imunologie $7 D001323
650    _2
$a kultivované buňky $7 D002478
650    _2
$a dermatomyozitida $x imunologie $7 D003882
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a interferon typ I $x metabolismus $7 D007370
650    _2
$a systémový lupus erythematodes $x imunologie $7 D008180
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myozitida s inkluzními tělísky $x imunologie $7 D018979
650    _2
$a prospektivní studie $7 D011446
650    _2
$a proteiny vázající RNA $x imunologie $7 D016601
650    _2
$a signální transdukce $7 D015398
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vosslamber, S $u Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
700    1_
$a Tjärnlund, A $u Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden.
700    1_
$a de Jong, T D $u Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
700    1_
$a Betteridge, Z $u Pharmacy and Pharmacology, University of Bath, Bath, UK.
700    1_
$a McHugh, N $u Pharmacy and Pharmacology, University of Bath, Bath, UK.
700    1_
$a Plestilova, L $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Klein, M $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Padyukov, L $u Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden.
700    1_
$a Voskuyl, A E $u Department of Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, the Netherlands.
700    1_
$a Bultink, I E M $u Department of Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, the Netherlands.
700    1_
$a Michiel Pegtel, D $u Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
700    1_
$a Mavragani, C P $u Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA. Department of Experimental Physiology, University of Athens, Athens, Greece.
700    1_
$a Crow, M K $u Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Vencovsky, J $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Lundberg, I E $u Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden.
700    1_
$a Verweij, C L $u Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands. Department of Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, the Netherlands.
773    0_
$w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 84, č. 2 (2016), s. 100-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27173897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170425130154 $b ABA008
999    __
$a ok $b bmc $g 1200326 $s 974639
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 84 $c 2 $d 100-9 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace